Robert W. Baird Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $180.00

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective lifted by Robert W. Baird from $157.00 to $180.00 in a report released on Friday morning, Benzinga reports. They currently have an outperform rating on the stock.

Several other analysts have also issued reports on NBIX. Oppenheimer boosted their price target on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the company an outperform rating in a research report on Thursday, May 2nd. Citigroup boosted their price objective on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the company a neutral rating in a research note on Friday, May 3rd. StockNews.com cut shares of Neurocrine Biosciences from a strong-buy rating to a buy rating in a research note on Saturday, July 27th. Needham & Company LLC reaffirmed a hold rating on shares of Neurocrine Biosciences in a research note on Thursday. Finally, BMO Capital Markets boosted their price objective on shares of Neurocrine Biosciences from $129.00 to $138.00 and gave the company a market perform rating in a research note on Thursday, May 2nd. Six analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Neurocrine Biosciences has a consensus rating of Moderate Buy and a consensus target price of $157.16.

Neurocrine Biosciences Trading Down 3.2 %

Shares of NASDAQ NBIX traded down $4.94 during midday trading on Friday, hitting $148.20. The company’s stock had a trading volume of 360,664 shares, compared to its average volume of 822,445. The stock has a fifty day moving average price of $139.82 and a 200 day moving average price of $138.46. Neurocrine Biosciences has a one year low of $100.52 and a one year high of $157.98. The firm has a market capitalization of $14.91 billion, a price-to-earnings ratio of 42.19 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The business had revenue of $590.20 million during the quarter, compared to the consensus estimate of $545.98 million. During the same period last year, the firm earned $0.95 EPS. The business’s revenue for the quarter was up 30.4% on a year-over-year basis. On average, equities research analysts predict that Neurocrine Biosciences will post 4.22 earnings per share for the current fiscal year.

Insider Activity at Neurocrine Biosciences

In related news, Director Stephen A. Sherwin sold 40,000 shares of the company’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the completion of the sale, the director now directly owns 26,504 shares in the company, valued at approximately $3,537,223.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Julie Cooke sold 900 shares of the company’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $150.04, for a total transaction of $135,036.00. Following the completion of the sale, the insider now directly owns 18,202 shares in the company, valued at approximately $2,731,028.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Stephen A. Sherwin sold 40,000 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the completion of the transaction, the director now owns 26,504 shares of the company’s stock, valued at $3,537,223.84. The disclosure for this sale can be found here. Insiders sold 80,436 shares of company stock worth $10,970,780 in the last three months. 4.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Neurocrine Biosciences by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock worth $1,369,673,000 after purchasing an additional 220,598 shares in the last quarter. Brown Advisory Inc. grew its position in shares of Neurocrine Biosciences by 2.2% in the 4th quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock worth $146,703,000 after buying an additional 23,831 shares during the period. Bank of New York Mellon Corp grew its position in shares of Neurocrine Biosciences by 1.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company’s stock worth $128,639,000 after buying an additional 13,069 shares during the period. Los Angeles Capital Management LLC grew its position in shares of Neurocrine Biosciences by 66.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock worth $121,007,000 after buying an additional 364,986 shares during the period. Finally, Vestal Point Capital LP purchased a new stake in shares of Neurocrine Biosciences in the 4th quarter worth about $105,408,000. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.